COVID-19 Research Visit UCLB’s dedicated e-lucid site to access free technologies for tackling COVID-19. READ MORE Image Credit: James Tye/UCL > OUR TECHNOLOGIES We market UCL innovations that have a real and positive impact on people's lives. READ MORE OUR SPINOUTS We’re committed to supporting and nurturing our spinouts. READ MORE SUPPORT FOR RESEARCHERS We’re ideally positioned to help and guide you at every step of your journey from innovation to impact. READ MORE
What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

UCL Business wins in the KE Awards 2020

UCL Business (UCLB) has won the Knowledge Exchange External Initiative of the Year in this year’s KE Awards organised by Praxis-Auril.

Read More
Featured Technology—

Quadruplex-binding compounds – a novel anticancer strategy

We have a first-in-class optimized small-molecule drug candidate ready for IND enabling studies with superior efficacy and activity against pancreatic cancer compared to existing agents, together with a distinct mechanism of action.

Read more
Spotlight—

An introduction to UCLB’s new Associate Director of BioPharm

We recently interviewed Associate Director of BioPharm, Dr Mark Fisher, about his new position, the ever-developing field of technology transfer, and the importance of commercialisation in society today.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

UCLB spinout Freeline Closes $120 Million Series C Financing Round

/ UCLB News
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases,  announced the closing of a $120 ...

UCL Business wins in the KE Awards 2020

/ UCLB News
LONDON – 25th June 2020 – UCL Business (UCLB) has won the Knowledge Exchange External Initiative of the Year in ...

UCLTF supports UCL cancer antibody therapies for Covid-19

/ UCLTF News
UCL Technology Fund (UCLTF), managed by AlbionVC in collaboration with UCL Business  (UCLB), has funded UCL’s Cancer Institute in repurposing ...

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

/ Spinout News
Achilles Therapeutics was formed in October 2016 by Syncona Ltd and Cancer Research Technology, with the support of UCLB and ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Commercialising technology since 1993

0
Spinout companies in the UCLB portfolio
0
Active licences
0
Drug discovery projects in development
0
New UK patent applications

As of July 2019

"With UCLB's excellent advice, support and business expertise TrimTots is running and ready to roll!" Dr Julie Lanigan, Co-Founder of TrimTots "We could not have done this without UCLB. Their advice, guidance and expertise was invaluable" Professor Bobby Gaspar, Chief Scientific Officer, Orchard Therapeutics "UCLB’s input and support have been invaluable. Professional, expert and a pleasure to work with" Professor Elizabeth Murray, Founder of HeLP Digital CIC "UCLB are business savvy but also have a sensitive understanding of research. I am very grateful and significantly wealthier!" Professor Anthony Finkelstein, Systemwire/Message Automation “The valuable advice and support UCLB provided us with gave us the confidence and infrastructure to launch the Print Fair” Professor Susan Collins, Slade School of Fine Art Photo Jim Wileman © 2015 Royal Albert Memorial Museum & Art Gallery, Exeter City Council “UCLB are a great source of talent, expertise and experience, and have been super helpful for us over the years” Dr Daniel Hulme, CEO of Satalia "UCLB's experience and advice has proved pivotal in our development as a company" Rael Cline, CEO of MediaGamma